$24.93
+1.14 (+4.79%)
Open$23.97
Previous Close$23.79
Day High$25.10
Day Low$23.45
52W High$34.19
52W Low$14.72
Volume—
Avg Volume281.8K
Market Cap1.30B
P/E Ratio—
EPS$-1.64
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.95M | 9.1K | 117.17M |
| Net Income | -68,131,365 | -50,362 | -10,038,830 |
| Profit Margin | -980.9% | -582.6% | -8.6% |
| EBITDA | -77,346,941 | -48,936 | -16,056,956 |
| Free Cash Flow | — | — | -11,744,338 |
| Rev Growth | +147.5% | +60.5% | +1.7% |
| Debt/Equity | — | 0.51 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |